05
Safety

Are adverse effects observed significantly higher following the second dose as opposed to the first dose for the mRNA vaccines?

0:54
19
Views
Перегляди
Visualizaciones
Просмотров
Zobrazení
2
Likes
Лайки
Me gusta
Любит
Líbí
12/9/2021

Reactogenicity and adverse events were generally milder and less frequent in clinical trial participants in the older group (≥55 years of age) compared with the younger group (18-55 years of age) and tended to increase after the second dose for the mRNA vaccines. Reactogenicity was mostly mild to moderate and short-lived after dosing for both adult age groups (median onset was 0-2 days after either dose for a median duration of 1 - 2 days).

Tags
Etiquetas
Теги
Značky